Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Z Best Place to Talk Stocks -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (40566)	6/13/2002 8:21:15 AM
From: Larry S.	Read Replies (1) \| Respond to of 53068

Ailing Bristol-Myers Seeks Options to Aid Its Pipeline By JOANN S. LUBLIN and RACHEL ZIMMERMAN Staff Reporters of THE WALL STREET JOURNAL Beleaguered drug giant Bristol-Myers Squibb Co. has asked Goldman Sachs Group Inc. to explore a host of alternative strategies that might help remedy its looming drug-pipeline problems, said a person familiar with the situation. Among those alternatives are a sale of the entire company, a merger of equals, a major acquisition or a sizable equity stake in a promising smaller company, such as the deal made last year with ImClone Systems Inc., this person said. Bob Laverty, a spokesman for Bristol-Myers, wouldn't confirm or deny talks between the drug company and Goldman. "To us, it's speculation, and we don't comment on rumors or speculation," he said. Goldman Sachs also declined to comment. Rumors have been rampant in recent weeks that the New York pharmaceuticals maker, plagued by problems on several fronts, is looking for a buyer or merger for salvation. Patents on three of its top-selling drugs recently expired, 29 state attorneys general are suing the company for blocking generic competition, and the U.S. Federal Trade Commission is investigating alleged anticompetitive actions. In the latest blow, Sam Waksal, former chief executive officer of Bristol's biotech partner, ImClone, was arrested Wednesday and charged with insider trading. Bristol agreed to pay $2 billion to the New York biotech company last year to co-develop and market the cancer drug Erbitux, which has been buffeted by the events surrounding the company. So far, however, "there have been zero discussions," a person said, between Bristol CEO Peter Dolan and leaders of three companies most mentioned as possible partners: GlaxoSmithKline PLC of the United Kingdom; Pharmacia Corp. of Peapack, N.J.; or Wyeth of Madison, N.J. Nor have there been any preliminary merger chats between lower-level officials at Bristol-Myers and Glaxo. However, it is likely that Bristol-Myers, with a market capitalization of about $50 billion, would seriously consider an attractive friendly offer from Glaxo, according to someone familiar with Bristol-Myers's thinking. A Glaxo representative said the drug maker doesn't comment on market rumors, but "we're always looking at opportunities in the marketplace, particularly in products to fill late-stage pipeline." Another potential partner, though mentioned less frequently, is Aventis SA. The French company, seeking to expand in the U.S. market, wouldn't comment. Hey Dan, is Rachel your niece????? ggg

To: DanZ who wrote (40566)	6/13/2002 11:36:52 AM
From: Kelvin Taylor	Read Replies (2) \| Respond to of 53068

"Since when is last summer just like this summer?" look at the numbers and see from Feb 1 - June 12, 2001 NAZ lost -491 pts or 18% from Feb 1 - June 12, 2002 NAZ lost -410 pts or 21% what happen from June 12, 2001 til Sept 1? NAZ lost another -223 or 11% history may not repeat, but one must be full aware of past pricing patterns. what catalyst makes this market go higher? we are now about to enter the warning season so anything is possible. and the market may very well become more cautious, IMO.